Annual CFI
-$86.57 M
-$40.58 M-88.25%
31 December 2023
Summary:
CymaBay Therapeutics annual cash flow from investing activities is currently -$86.57 million, with the most recent change of -$40.58 million (-88.25%) on 31 December 2023. During the last 3 years, it has fallen by -$135.16 million (-278.17%).CBAY Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$42.11 M
-$57.57 M-372.34%
31 December 2023
Summary:
CymaBay Therapeutics quarterly cash flow from investing activities is currently -$42.11 million, with the most recent change of -$57.57 million (-372.34%) on 31 December 2023.CBAY Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$86.57 M
-$50.46 M-139.76%
31 December 2023
Summary:
CymaBay Therapeutics TTM cash flow from investing activities is currently -$86.57 million, with the most recent change of -$50.46 million (-139.76%) on 31 December 2023.CBAY TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CBAY Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -278.2% | -74.9% | -278.2% |
| 5 y5 years | -152.0% | -554.7% | -152.0% |
CBAY Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -278.2% | -189.6% | -161.2% |
CymaBay Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$86.57 M(+88.3%) | -$42.11 M(-372.3%) | -$86.57 M(+139.8%) |
| Sept 2023 | - | $15.46 M(+2050.3%) | -$36.11 M(-35.7%) |
| June 2023 | - | $719.00 K(-101.2%) | -$56.12 M(+0.9%) |
| Mar 2023 | - | -$60.64 M(-825.7%) | -$55.64 M(+21.0%) |
| Dec 2022 | -$45.98 M(-194.6%) | $8.36 M(-283.7%) | -$45.98 M(-41.4%) |
| Sept 2022 | - | -$4.55 M(-479.7%) | -$78.42 M(+72.1%) |
| June 2022 | - | $1.20 M(-102.3%) | -$45.58 M(+19.6%) |
| Mar 2022 | - | -$50.99 M(+111.8%) | -$38.09 M(-178.4%) |
| Dec 2021 | $48.59 M(+1.3%) | -$24.08 M(-185.1%) | $48.59 M(-28.9%) |
| Sept 2021 | - | $28.29 M(+226.0%) | $68.32 M(-5347.1%) |
| June 2021 | - | $8.68 M(-75.7%) | -$1.30 M(-103.5%) |
| Mar 2021 | - | $35.69 M(-920.7%) | $37.02 M(-22.8%) |
| Dec 2020 | $47.96 M(-239.6%) | -$4.35 M(-89.5%) | $47.96 M(-22.1%) |
| Sept 2020 | - | -$41.33 M(-187.9%) | $61.57 M(-56.5%) |
| June 2020 | - | $47.00 M(+0.8%) | $141.40 M(+562.9%) |
| Mar 2020 | - | $46.63 M(+403.5%) | $21.33 M(-162.1%) |
| Dec 2019 | -$34.35 M(-36.5%) | $9.26 M(-76.0%) | -$34.35 M(+104.0%) |
| Sept 2019 | - | $38.51 M(-152.7%) | -$16.84 M(-61.5%) |
| June 2019 | - | -$73.07 M(+708.0%) | -$43.74 M(-265.0%) |
| Mar 2019 | - | -$9.04 M(-133.8%) | $26.50 M(-149.0%) |
| Dec 2018 | -$54.11 M | $26.77 M(+130.6%) | -$54.11 M(-28.6%) |
| Sept 2018 | - | $11.61 M(-509.6%) | -$75.78 M(-52.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2018 | - | -$2.83 M(-96.8%) | -$159.29 M(+3.5%) |
| Mar 2018 | - | -$89.66 M(-1858.6%) | -$153.96 M(+128.0%) |
| Dec 2017 | -$67.53 M(-348.9%) | $5.10 M(-107.1%) | -$67.53 M(+7.5%) |
| Sept 2017 | - | -$71.90 M(-2973.9%) | -$62.81 M(-761.8%) |
| June 2017 | - | $2.50 M(-177.6%) | $9.49 M(+122.1%) |
| Mar 2017 | - | -$3.22 M(-132.8%) | $4.27 M(-84.2%) |
| Dec 2016 | $27.13 M(-344.8%) | $9.82 M(+2385.6%) | $27.13 M(+15.3%) |
| Sept 2016 | - | $395.00 K(-114.5%) | $23.52 M(-1391.7%) |
| June 2016 | - | -$2.72 M(-113.8%) | -$1.82 M(-124.4%) |
| Mar 2016 | - | $19.63 M(+216.1%) | $7.45 M(-167.2%) |
| Dec 2015 | -$11.08 M(-34.6%) | $6.21 M(-124.9%) | -$11.08 M(-23.0%) |
| Sept 2015 | - | -$24.95 M(-480.6%) | -$14.40 M(+6132.0%) |
| June 2015 | - | $6.55 M(+496.4%) | -$231.00 K(-98.6%) |
| Mar 2015 | - | $1.10 M(-62.1%) | -$16.39 M(-3.2%) |
| Dec 2014 | -$16.94 M(+171.8%) | $2.90 M(-126.9%) | -$16.94 M(-36.1%) |
| Sept 2014 | - | -$10.78 M(+12.3%) | -$26.52 M(+71.8%) |
| June 2014 | - | -$9.60 M(-1846.2%) | -$15.44 M(+171.7%) |
| Mar 2014 | - | $550.00 K(-108.2%) | -$5.68 M(-8.8%) |
| Dec 2013 | -$6.23 M(-156.6%) | -$6.68 M(-2327.0%) | -$6.23 M(-1484.7%) |
| Sept 2013 | - | $300.00 K(+100.0%) | $450.00 K(+200.0%) |
| June 2013 | - | $150.00 K(>+9900.0%) | $150.00 K(>+9900.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
| Dec 2012 | $11.01 M | - | - |
FAQ
- What is CymaBay Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for CymaBay Therapeutics?
- What is CymaBay Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for CymaBay Therapeutics?
- What is CymaBay Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for CymaBay Therapeutics?
What is CymaBay Therapeutics annual cash flow from investing activities?
The current annual CFI of CBAY is -$86.57 M
What is the all time high annual CFI for CymaBay Therapeutics?
CymaBay Therapeutics all-time high annual cash flow from investing activities is $48.59 M
What is CymaBay Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of CBAY is -$42.11 M
What is the all time high quarterly CFI for CymaBay Therapeutics?
CymaBay Therapeutics all-time high quarterly cash flow from investing activities is $47.00 M
What is CymaBay Therapeutics TTM cash flow from investing activities?
The current TTM CFI of CBAY is -$86.57 M
What is the all time high TTM CFI for CymaBay Therapeutics?
CymaBay Therapeutics all-time high TTM cash flow from investing activities is $141.40 M